



First total synthesis of haplacutine C



Noriki Kutsumura^{a,b,*}, Keisuke Numata^b, Takao Saito^{b,*}

^a International Institute for Integrative Sleep Medicine (WPI-IIMS), University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan

^b Department of Chemistry, Faculty of Science, Tokyo University of Science, Kagurazaka, Shinjuku-ku, Tokyo 162-8601, Japan

ARTICLE INFO

Article history:

Received 31 August 2016

Revised 12 October 2016

Accepted 20 October 2016

Available online 21 October 2016

Keywords:

Total synthesis

Haplacutine C

Natural product

Quinolinone alkaloid

Stille coupling

ABSTRACT

A total synthesis of haplacutine C has been achieved. The synthetic key features were the intramolecular aldol condensation for construction of the 4-quinolinone skeleton and the Stille coupling for elongation of the dienol side chain. In addition, the 4-O-protected-quinolines were also utilized as the synthetic equivalents of 4-quinolinone at the stage of side chain transformation.

© 2016 Elsevier Ltd. All rights reserved.

Introduction

In 2009, Staerk et al. identified the novel quinolinone alkaloids haplacutines A–F (Fig. 1)¹ together with several known related compounds from a crude extract of *Haplophyllum acutifolium* by their original method, viz., direct hyphenation of analytical-scale high-performance liquid chromatography, photo-diode array detection, mass spectrometry, solid-phase extraction, and nuclear magnetic resonance spectroscopy (HPLC–PDA–MS–SPE–NMR). *H. acutifolium* is distributed from the Mediterranean parts of Europe and Africa to Eastern parts of Siberia, and in general, known as a rich source of quinolinone alkaloids. The extracts are widely used in traditional medicine because of their estrogenic, antifungal, antibacterial, and antiparasitic activity.² In fact, the extract including the haplacutines also showed antiplasmodial activity with IC₅₀ <12 µg/mL in vitro (chloroquine-sensitive *Plasmodium falciparum* 3D7 strain).¹ We therefore initiated the synthesis of the series of haplacutines A–F, with the exception of the isolated haplacutine E, because of our interest in the bioactivity of each of the quinolinone alkaloids. We describe herein the synthesis of haplacutine C (**1**) (Fig. 1).

First, we prepared the aldol cyclization precursor **3** by amidation of 2'-aminoacetophenone with the known carboxylic acid (±)-**2**³ using 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI·HCl) (Scheme 1). Then, the intramolecular

aldol condensation of **3** in the presence of *t*-BuOK⁴ under optimized conditions⁵ gave the desired 4-quinolinone derivative **4** in 66% yield together with the undesired 2-quinolinone derivative **5** in 30% yield. After separation of both isomers by column chromatography on silica gel, we attempted a bromine addition of the terminal double bond of the side-chain in **4** to transform a prerequisite terminal triple bond at the following step by utilizing the method of double HBr-elimination.⁶ Unfortunately, this approach under any conditions was unsuccessful, resulting in the formation of an undesired 3-bromo-4-quinolinone derivative **7** in quantitative yield.

After we had converted the 4-quinolinone derivative **4** into the 4-(4-methoxybenzyloxy)quinoline **8** to avoid the generation of the undesired **7**, the alkene **8** was successfully transformed into the desired alkyne **10** by way of the double HBr-elimination from vicinal dibromide **9** (Scheme 2).⁶ Hydrostannation of **10** using 2 mol % of Pd₂(dba)₃ with 8 mol % of *t*-Bu₃P gave (*E*)-1-tributylstannyl-1-alkene **11** with high regioselectivity (>95/5).⁷ Finally, the important intermediate (*E*)-alkenyl iodide **12** was obtained in quantitative yield from **11**.⁸

At the final synthetic stage, we first prepared (*E*)-but-1-enyl-tributylstannane (**14**)⁹ from the known **13**,¹⁰ then attempted the Stille coupling of **12** with **14**, followed by the deprotection of both PMB groups to achieve the first synthesis of **1** (Scheme 3). However, the expected PMB-deprotection step of the coupling product **15** gave complex mixtures under any reaction conditions (TFA,¹¹ CAN, 1 M HCl aq, or DDQ), though the carbon elongation proceeded smoothly. This outcome is probably because of the rapid decomposition of the diene moiety of **15** under the PMB cleavage conditions.

* Corresponding authors. Tel./fax: +81 29 853 6568.

E-mail addresses: kutsumura.noriki.gn@u.tsukuba.ac.jp (N. Kutsumura), tsaito@rs.kagu.tus.ac.jp (T. Saito).







Figure 1. Structure of haplacutines A–F from *H. acutifolium*.



Scheme 1. Reagents and conditions: (a) EDCI·HCl (2.0 equiv), *N,N*-dimethyl-4-aminopyridine (2.0 equiv), CH₂Cl₂, rt, 2 h (93%); (b) *t*-BuOK (3.0 equiv), toluene, reflux, 8 h (4: 66%, 5: 30%); (c) Pyr·HBr₃ (1.1 equiv), DMF, rt, 30 min (100%).



Scheme 2. Reagents and conditions: (a) NaH (2.0 equiv), PMBCl (1.0 equiv), DMF, rt, 12 h (93%); (b) Pyr·HBr₃ (1.1 equiv), CH₂Cl₂, rt, 2 h (84%); (c) tetrabutylammonium hydroxide (10% in MeOH, 5.0 equiv), molecular sieves 13× (10 times the mass of 9), DMSO, 60 °C, 2 h (92%); (d) *n*-Bu₃SnH (1.5 equiv), Pd₂(dba)₃ (2 mol %), *t*-Bu₃P (8 mol %), toluene, rt, 30 min (80%); (e) I₂ (1.1 equiv), CH₂Cl₂, rt, 30 min (97%).



Scheme 3. Reagents and conditions: (a) LiAlH₄ (2.5 equiv), THF, rt, 2 h (98%); (b) **14** (3.0 equiv), PdCl₂(PPh₃)₂ (10 mol %), DMF, 55 °C, 5.5 h (53%); (c) TFA–CH₂Cl₂, rt, 1 h (99%); (d) *t*-BuOK (2.1 equiv), AcCl (5.0 equiv), Et₃N (6.0 equiv), THF, rt, 1 h (84%); (e) **14** (3.0 equiv), Pd(CH₃CN)₂Cl₂ (30 mol %), DMF, rt, 2 h (61%); (f) K₂CO₃ (4.0 equiv), MeOH, rt, 1.5 h (99%).

Therefore, the PMB groups of **12** were replaced with acetyl groups by TFA hydrolysis¹¹ and subsequent acetylation. Finally, the Stille coupling¹² of **17** with **14** gave diene **18** with high stereoselectivity (*E*-form, >99/1) albeit in moderate yield, and then the deprotection of both acetyl groups under mild basic condition succeeded to give haplacutine C (**1**) in quantitative yield, which was identical spectroscopically to that reported by Staerk et al.^{1,13}

In conclusion, we achieved the total synthesis of haplacutine C (**1**) for the first time, by a method that ensured the structure **1**, which was proposed previously.¹ In our synthesis, the intramolecular aldol condensation was used for the formation of 4-quinolinone skeleton and the Stille coupling was used for the carbon side-chain elongation. This synthetic method can be utilized for other haplacutines and related compounds. Further investigation is in progress.

Acknowledgments

This work was partly supported by the Sasakawa Scientific Research Grant from the Japan Science Society and the Tokyo Ohka Foundation for The Promotion of Science and Technology.

Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.tetlet.2016.10.070>.

References and notes

- Staerk D, Kesting JR, Sairafianpour M, Witt M, Asili J, Emami SA, Jaroszewski JW. *Phytochemistry*. 2009;70:1055–1061.
- Nazrullaev SS, Bessonova IA, Akhmedkhodzhaeva KhS. *Chem. Nat. Compd.* 2001;37:551–555.
- (a) Jana N, Mahapatra T, Nanda S. *Tetrahedron: Asymmetry*. 2009;20:2622–2628; (b) Giri AG, Mondal MA, Puranik VG, Ramana CV. *Org. Biomol. Chem.* 2010;8:398–406; (c) Wadavrao SB, Ghogare RS, Narsaiah AV. *Synthesis*. 2015;47:2129–2137.
- (a) Hadjeri M, Mariotte A-M, Boumendjel A. *Chem. Pharm. Bull.* 2001;49:1352–1355; (b) Jones CP, Anderson KW, Buchwald SL. *J. Org. Chem.* 2007;72:7968–7973;

- (c) Marques EF, Bueno MA, Duarte PD, Silva LRSP, Martinelli AM, dos Santos CY, Severino RP, Brömme D, Vieira PC, Corrêa AG. *Eur. J. Med. Chem.*. 2012;54:10–21.
5. For example, NaOH-promoted cyclization in 1,4-dioxane (see Ref. 4b) gave 38% of **4** and 55% of **5**.
6. (a) Kutsumura N, Kubokawa K, Saito T. *Synlett*. 2010;2717–2720;
(b) Kutsumura N, Kubokawa K, Saito T. *Synthesis*. 2011;2377–2382;
(c) Kutsumura N, Inagaki M, Kiriseko A, Saito T. *Synthesis*. 2015;47:1844–1850.
7. Darwish A, Lang A, Kim T, Chong JM. *Org. Lett.*. 2008;10:861–864.
8. Matsuda M, Yamazaki T, Fuhshuku K, Sugai T. *Tetrahedron*. 2007;63:8752–8760.
9. (a) Jackson SK, Banfield SC, Kerr MA. *Org. Lett.*. 2005;7:1215–1218;
(b) Kusakabe T, Kawai Y, Kato K. *Org. Lett.*. 2013;15:5102–5105;
(c) Chandrasoma N, Brown N, Brassfield A, Nerurkar A, Suarez S, Buszek KR. *Tetrahedron Lett.*. 2013;54:913–917.
10. Cerri A, Almirante N, Barassi P, Benicchio A, Fedrizzi G, Ferrari P, Micheletti R, Quadri L, Ragg E, Rossi R, Santagostino M, Schiavone A, Serra F, Zappavigna MP, Melloni P. *J. Med. Chem.*. 2000;43:2332–2349.
11. Farhanullah, Kim SY, Yoon E-J, Choi E-C, Kim S, Kang T, Samrin F, Puri S, Lee J. *Bioorg. Med. Chem.*. 2006;14:7154–7159.
12. (a) Stille JK. *Angew. Chem., Int. Ed.*. 1986;25:508–524;
(b) Paquette LA, Barriault L, Pissarnitski D, Johnston JN. *J. Am. Chem. Soc.*. 2000;122:619–631;
(c) Nicolaou KC, Bulger PG, Sarlah D. *Angew. Chem., Int. Ed.*. 2005;44:4442–4489.
13. *Synthetic sample's spectroscopic data*: IR (neat) 3378, 3278, 2962, 2923, 2854, 1735, 1635, 1596, 1511 cm^{-1} ; ^1H NMR (300 MHz, CD_3CN) δ = 0.98 (t, J = 7.5 Hz, 3H), 1.87 (m, 2H), 2.08 (m, 2H), 2.68 (m, 2H), 3.25 (br s, 1H), 4.11 (m, 1H), 5.60 (dd, J = 15.1, 6.6 Hz, 1H), 5.73 (dt, J = 15.1, 6.6 Hz, 1H), 5.98 (s, 1H), 6.03 (dd, J = 15.1, 10.6 Hz, 1H), 6.18 (dd, J = 15.1, 10.6 Hz, 1H), 7.28 (dd, J = 8.0, 7.4 Hz, 1H), 7.46 (d, J = 8.4 Hz, 1H), 7.59 (dd, J = 8.4, 7.4 Hz, 1H), 8.12 (d, J = 8.0 Hz, 1H), 9.94 (br s, 1H); ^{13}C NMR (150 MHz, CD_3CN) δ = 13.8 (CH_3), 26.3 (CH_2), 30.8 (CH_2), 36.8 (CH_2), 71.6 (CH), 108.9 (CH), 118.6 (CH), 124.0 (CH), 125.9 (C), 126.0 (CH), 129.7 (CH), 131.3 (CH), 132.6 (CH), 134.8 (CH), 137.3 (CH), 141.3 (C), 154.8 (C), 178.9 (C); HRMS-ESI: m/z $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{18}\text{H}_{21}\text{NO}_2\text{Na}$, 306.1465, found: 306.1463.